Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway

Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway

Introduction: The anti-cancer medication doxorubicin (Dox) is largely restricted in clinical usage due to its significant cardiotoxicity. The only medication approved by the FDA for Dox-induced cardiotoxicity is dexrazoxane, while it may reduce the sensitivity of cancer cells to chemotherapy and is...

Full description

Bibliographic Details
Main Authors: Mingge Ding, Rui Shi, Feng Fu, Man Li, Dema De, Yanyan Du, Zongfang Li
Format: Article
Language:English
Published: Elsevier 2023-05-01
Series:Journal of Advanced Research
Subjects:
Doxorubicin
Paeonol
Mitochondrial fusion
PKCε
Stat3
Mfn2
Online Access:http://www.sciencedirect.com/science/article/pii/S2090123222001564

Similar Items

Similar Items